Bratschi advised UBS Switzerland on a secured financing for Baar-based Swiss Physio Partner (SSP). Swiss Physio Partner Group plans to utilise the proceeds from the loan in question to further develop its network of physiotherapy
Tags :dx3
Bratschi has advised the owners of Dokspot — a specialist in electronic Instructions for Use solutions for IVD and medical device manufacturers — on the company’s sale to Matrix One, a portfolio company of Lauxera Capital
Bratschi advised customer experience service provider Avaris CX on the acquisition of Callpoint, including its subsidiary Tempobrain. The transaction results in the creation of a customer experience service provider active in the DACH region. The
Schellenberg Wittmer advised ams-Osram — a specialist in intelligent sensors and emitters listed on SIX Swiss Exchange — on the carve-out of the augmented reality and virtual reality business to AlphaLum, a newly created subsidiary, as
Wenger Vieli advised vascular implants specialist Xeltis on its financing round, raising approximately EUR 50 million. The sum includes up to EUR 37.5 million from the European Investment Bank (EIB) and EUR 10 million from existing shareholders such
Wenger Vieli promoted Jonas Bühlmann (pictured) to the partnership, effective as of January 1st 2026. Part of the firm since 2021, Bühlmann is active within the areas of corporate tax, M&A tax and
Sedrun Solar – a project for a large-scale alpine photovoltaic plant in Switzerland – secured a syndicated project financing led by Zürcher Kantonalbank. In connection with the operation, Bratschi advised Sedrun Solar, while Walder Wyss represented
Bratschi advised the sellers of historic Bernese brewery Rugenbräu on succession planning. In particular, two members of the company’s management board, CEO Remo Kobluk and CFO Christian Schneiter, are taking over the traditional
Bratschi represented the University Hospital Basel in the merger proceedings before the COMCO, as the commission examined the hospital’s takeover of the Claraspital Basel and the other companies in the Clara Group, and decided
Vischer advises Oculis Holding, as the globally active biopharmaceutical company announced the pricing of offerings for an aggregate of 5,432,098 of its ordinary shares. The stocks value at $20.25 per unit, for total gross proceeds of USD 110
